



SymBio Pharmaceuticals Limited
San-Ei Building, 5-23-7 Shimbashi, Minato-ku, Tokyo 105-0004, Japan
Tel: +81-3-5472-1125 Fax: +81-3-5472-3054 <http://www.symbiosis.co.jp/>

January 7, 2008

SymBio Pharmaceuticals Limited

Fuminori Yoshida

Representative Director, President and Chief Executive Officer

Cephalon Submits New Drug Application for TREANDA® for the Treatment of Patients with Relapsed Indolent Non-Hodgkin's Lymphoma

12/31/2007

Frazer, PA – December XX, 2007 – Cephalon, Inc. (Nasdaq: CEPH) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) requesting approval of TREANDA® (bendamustine HCl) for Injection for the treatment of patients with indolent B-cell non-Hodgkin's lymphoma (NHL) who have progressed during or following treatment with rituximab or a rituximab-containing regimen. According to the National Cancer Institute, an estimated 30,000 people in the United States will be diagnosed in 2007 with indolent NHL, a serious and slow growing cancer of the lymphatic system that is difficult to treat because patients are prone to relapse after treatment.

“This is an exciting milestone for Cephalon as it is our second NDA filing for TREANDA® submitted to the FDA in 2007 and TREANDA® is the lead product in our diverse and progressing oncology pipeline,” said Dr. Lesley Russell, Executive Vice President, Worldwide Medical and Regulatory Operations. “The clinical data supporting this submission highlight the potential of TREANDA® to make a meaningful difference for patients with relapsed indolent NHL.”

The TREANDA® NDA for relapsed indolent NHL is supported by three studies in patients with NHL, including one in combination with rituximab. In these studies, patients treated with TREANDA® had a high rate of response and a manageable and tolerable side effect profile, with adverse events similar to those observed with other chemotherapy agents.

[Company Profile]

About SymBio Pharmaceuticals Limited

SymBio Pharmaceuticals' focus is on oncology/hematology and autoimmune disease therapies. Established in March 2005 by Fuminori Yoshida, who previously served as both Corporate Vice President of Amgen Inc. and president of Amgen Japan, SymBio Pharmaceuticals' underlying corporate philosophy is "delivering hope to patients in need," and the company aims to address unmet medical needs of patients in Japan by cultivating a mutually beneficial or symbiotic relationship among physicians, scientists, regulatory agencies, and investors. SymBio Pharmaceuticals core philosophy is that profitability and socially responsibility as a pharmaceutical enterprise can go hand in hand, and need not be mutually exclusive.

For further information, please contact:

Osamu Ogawa, Board Director, Senior Corporate Officer, COO

SymBio Pharmaceuticals Limited

Tel: +81(0) 3 5472 1123

E-mail: Please send your inquiry through "INQUIRY" in our homepage

URL: <http://www.symbiosis.co.jp>